TDC
BCRX icon

Thompson Davis & Co’s BioCryst Pharmaceuticals BCRX Stock Holding History

Thompson Davis & Co’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-500
Closed -$6K – 1143
2014
Q2 		$6K Buy
+500
New +$4.87K 0.01% 571

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Thompson Davis & Co's BCRX Position: Q3 2014 in Review

Thompson Davis & Co sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2014, closing a stake of 500 shares — an estimated $6K sold.

Thompson Davis & Co first reported a position in BCRX in Q2 2014 and held it in 1 quarter. The position peaked at $6K in Q2 2014. 102 funds tracked by Wall St. Rank hold BCRX as of Q3 2014.

  • Thompson Davis & Co reported no remaining BioCryst Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Thompson Davis & Co sold 500 BioCryst Pharmaceuticals shares in Q3 2014, an estimated $6K.
  • Thompson Davis & Co first reported a position in BioCryst Pharmaceuticals in Q2 2014 and held it in 1 quarter.
  • Thompson Davis & Co's BioCryst Pharmaceuticals position peaked at $6K in Q2 2014.
  • 102 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2014.

Based on Thompson Davis & Co's 13F filing for Q3 2014, filed 4 Nov 2014.